HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Pregnancy outcomes of women exposed to laninamivir during pregnancy

This item is licensed under: Creative Commons Attribution 3.0 Unported

Files in This Item:
pds3684.pdf77.46 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Pregnancy outcomes of women exposed to laninamivir during pregnancy
Authors: Minakami, Hisanori Browse this author →KAKEN DB
Kubo, Takahiko Browse this author
Nakai, Akihito Browse this author →KAKEN DB
Saito, Shigeru Browse this author →KAKEN DB
Unno, Nobuya Browse this author
Keywords: antiviral drug
Issue Date: Oct-2014
Publisher: Wiley-Blackwell
Journal Title: Pharmacoepidemiology and drug safety
Volume: 23
Issue: 10
Start Page: 1084
End Page: 1087
Publisher DOI: 10.1002/pds.3684
Abstract: Purpose The purpose of this study is to assess pregnancy outcomes of women treated with a novel neuraminidase inhibitor, laninamivir, during pregnancy. Methods A retrospective review of pregnancy outcomes of 112 pregnant women who were given laninamivir for treatment of influenza was performed. Possible adverse events, including miscarriages, preterm birth, foetal malformation and any neonatal morbidity requiring treatment, were assessed. Results Seventeen, 39, 46 and 10 women were administered a single inhaled dose of 20 or 40 mg of laninamivir at gestational week (GW) 3-11, 12-21, 22-36 and 37 or more, respectively. One (1.8%) of 56 women with laninamivir at GW <22 experienced miscarriage at GW <12. The remaining 111 women gave birth to 111 viable infants but at preterm (GW <37) in nine (8.8%) of 102 women with laninamivir at GW <37. Three (2.7%) of the 111 newborns had malformations: forefoot varus deformity, foot polydactyly and cleft lip in one each born to a mother taking laninamivir atGW6, 17 and 21, respectively. Five neonates (4.5%) were small for gestational age. Eleven (9.9%), five (4.5%) and no neonates required phototherapy for jaundice, transient respiratory supports for respiratory distress syndrome (n = 2) or transient tachypnoea of the newborn (n = 3), and glucose administration for hypoglycaemia, respectively. Conclusions Although this study included a small number of study women and no control women, the results suggested that maternal exposure to laninamivir did not increase the rate of adverse pregnancy and foetal outcomes. (C) 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 水上 尚典

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 - Hokkaido University